Physician profile
Zulehuma Rather
NPI 1386966083
$664.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $100 · 2021: $157 · 2022: $59.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $256.77 | 2019-2022 | |
| Lilly USA, LLC | $109.69 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $102.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.23 | 2019-2021 | |
| Abbvie INC. | $27.33 | 2022 | |
| Dynavax Technologies Corporation | $26.42 | 2020-2021 | |
| Dexcom, INC. | $19.93 | 2021 | |
| Eisai INC. | $19.23 | 2021 | |
| Sanofi Pasteur INC. | $18.94 | 2021 | |
| Horizon Therapeutics Plc | $18.16 | 2022 | |
| Glaxosmithkline, LLC. | $13.60 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zulehuma Rather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.